“Medication Adherence And Pharmacotherapy Clinic Utilization In An Aprn (advanced Practice Registered Nurse) Led Heart Failure Clinic: A Comparative Analysis Of Entresto, Jardiance, And Farxiga”

Objective

To assess and compare medication adherence patterns while utilizing the pharmacotherapy clinic that leverages the federal 340B drug program among heart failure patients under the care of APRN. Entresto, Jardiance, and Farxiga are the focus of this analysis due their relatively increased cost.

Methods

Data were collected over a 24-month period for the Heart Failure Clinic and over 64 months for the Pharmacotherapy clinic, focusing on patients prescribed Entresto, Jardiance, or Farxiga. The study included heart failure patients aged 18 years and older, and were categorized based on medication regimens: Entresto, Jardiance, Farxiga, or combination therapy. The data collected included pharmacotherapy clinic utilization as well as prescription tracking of patients that have stayed on the aforementioned medications. The primary outcome was sustained medication adherence rates in spite of patient ability to pay for each medication and the secondary outcome is reduction in hospitalization and improvement in overall patient well being.

Results

Entresto: Patient count increased from 353 to 564 between March 2022 and March 2024, resulting in a 59.8% rise. Jardiance: Patient count grew from 225 to 456 during the same period, representing a substantial 102.7% increase. Farxiga: The number of patients went up from 83 to 168, indicating a 102.4% surge.

Conclusions

In this comparative analysis, medication adherence patterns and pharmacotherapy clinic utilization among heart failure patients under the care of APRN were explored with a focus on three key medications: Entresto, Jardiance, and Farxiga. The findings shed light on critical aspects of patient management and treatment optimization, despite variations in patients’ ability to pay and insurance type. Sustained and increase in medication adherence rates were recorded due to the APRN`s pivotal role in ensuring patients commitment treatment plans by overcoming a principle barrier of medications cost by utilizing the Pharmacotherapy clinic by leveraging on the federal 340B drug program with reduced medication costs as provided by the Through this analysis, we sought to contribute valuable evidence that empowers APNPs, healthcare providers, and policymakers in their efforts to enhance HF management. Reduction in hospitalization rates and overall improvement in patient well-being were secondary outcomes of interest. While further research is needed, our study provides a foundation for future investigations.